Trials / Conditions / Stage III Bladder Cancer AJCC v8

Stage III Bladder Cancer AJCC v8

17 registered clinical trials studyying Stage III Bladder Cancer AJCC v8 — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bl NCT06764095	Mayo Clinic	Phase 4
Recruiting	An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Loc NCT06414317	Roswell Park Cancer Institute	N/A
Withdrawn	Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416	National Cancer Institute (NCI)	Phase 2
Recruiting	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Va NCT05756569	Emory University	Phase 2
Active Not Recruiting	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in NCT05092958	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104	M.D. Anderson Cancer Center	Phase 2
Terminated	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Du NCT04216290	National Cancer Institute (NCI)	Phase 2
Suspended	Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Gen NCT03375307	National Cancer Institute (NCI)	Phase 2
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Active Not Recruiting	Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelia NCT03854474	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952	National Cancer Institute (NCI)	Phase 2
Completed	Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Partici NCT03617913	Mayo Clinic	Phase 2
Active Not Recruiting	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta NCT03237780	National Cancer Institute (NCI)	Phase 2
Completed	Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy NCT03319745	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208	National Cancer Institute (NCI)	Phase 1